The global stem cell therapy market is projected to reach a size of USD 31.41 billion by 2030, growing at a CAGR of 13.73% during the forecast period from 2023 to 2030. The market was valued at USD 11.22 billion in 2022 and is expected to expand to USD 24.29 billion by 2028 due to factors such as accelerated funding for stem cell therapies, rising interest from investors, increased awareness of stem cell-based therapeutics, and advancements in research and development activities. Adult stem cells are predicted to dominate the market based on product type, while allogenic therapy is anticipated to have the largest share based on therapy type. The regenerative medicine segment is projected to register the largest share based on application, with North America accounting for the largest region in the market due to its advanced healthcare infrastructure and favorable reimbursement policies. Researchers are actively exploring new treatments using stem cell therapy against SARS CoV-2 virus.
Other trends related to stem cell therapy include increasing adoption for regenerative medicine, growing investment in research and development activities, favorable regulatory environment, expanding clinical applications, and technological advancements.
Pharmaceutical and biotechnology companies have reported the largest market share in 2022 due to increased